ftInvstr
ERIS · Healthcare ₹1255.5 +0.22% Mkt Cap ₹17415 Cr overvalued

ERIS

Healthcare Drug Manufacturers - Specialty & Generic
₹1255.5
+0.22% today · 30d +6.85%
as of 2026-11-09
Price · Daily Candles
AI narrative is temporarily unavailable for ERIS. The deterministic sections below render from live data.
₹ Latest Earnings · Q ending 2026-09-30
REVENUE
₹892 Cr
+12.61% YoY
NET PROFIT
₹187 Cr
+39.17% YoY
OPM
34.9%
-1.7pp YoY
EPS
₹13.26
PE 24.8
Intrinsic value · DCF ₹555.57 · Margin of safety -55.7% (overvalued) · FCF yield 1.38%
◇ Sector Position
PEERPEROCE %
ERIS24.814.0
SUNPHARMA37.7921.44
DIVISLAB93.121.56
ZYDUSLIFE28.424.22
+ 2 more peers — sign in to view
ML Forward Growth Predictions 🔒

9 ML-predicted forward-growth ranks across sales, EBIT, and FCF.

Sign up freeSign in
61
SCORE / 100
Overall
6-axis composite of the sections below.
Performance UNDERPERFORMER 20
Valuation REASONABLE 60
Growth STRONG 70
Profitability HIGH 75
Technicals NEUTRAL 50
Risk LOW 90
Key Stats
TTM PE
24.8
P/B
4.27
52W HIGH
₹1740.0
OFF HIGH
-27.84%
DIV YIELD
1.14%
MKT CAP
₹17415 Cr
◉ Active Signals
MACDBullish18.2117
RSI(14)Bullish62.53
Street Consensus
10 analysts
₹1514.4
mean target
Low ₹1140.0Now ₹1255.5High ₹1780.0
⧉ Strategy Fit 🔒

See which of ftInvstr's 50+ strategies hold ERIS and at what entry.

Sign up freeSign in